TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01123980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
Study: NCT04330482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE-Well App
Description: Participants randomized into this group will be instructed to use the CARE-Well App at least 4 times per week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet Links
Description: Participants randomized into this group will be instructed to use a computer tablet pre-loaded with a list of internet links relevant to dementia caregiving at least 4 times per week.
Study: NCT02238470

Intervention type: DRUG
Intervention: oral anticoagulants
Description: Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging
Study: NCT06684405

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sodium sodium fluoride solution (0.75 mg for subjects aged 12 and 1.0 mg for subjects aged 13)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Subjects in the control group received a daily dose of 0.5 ml sterile water to be added to 200 ml of milk.
Study: NCT03443180

Intervention type: OTHER
Group type: OTHER
Intervention: Gluten and Amylase Trypsin Inhibitors (ATI)-free diet
Description: Participants will be asked to avoid foods containing gluten and ATI (a similar protein found in grains) for 4 weeks.
Study: NCT03976843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: 18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
Study: NCT03739996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Cabotegravir (CAB)
Description: 30 mg tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Description: NRTIs will not be provided by the study. Participants will obtain NRTIs outside of the study through routine care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-Acting Injectable Cabotegravir (CAB LA)
Description: 600 mg loading dose followed by 400 mg maintenance doses administered by intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: 40 mg/kg administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) Oral ART
Description: SOC ART will not be provided by the study. Participants will obtain SOC ART outside of the study through routine care.
Study: NCT03848000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Programme
Description: Two sessions per week for 12 consecutive weeks. 30 minute education talks covering topics regarding the physical and mental health benefits of exercise and behaviour change. The following 30-60 minute exercise sessions will utilise pad-boxing, football, body-weight training and circuit training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NHS Standard Care
Description: Weekly one-to-one cognitive-behavioral counselling alcohol addiction support session lasting 1 hour. Drug therapy will be offered if indicated in line with standard therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NHS Standard Care
Description: Weekly one-to-one cognitive-behavioral counselling alcohol addiction support session lasting 1 hour. Drug therapy will be offered if indicated in line with standard therapy.
Study: NCT01105533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 6mg Capsule Twice Daily (Dose Expansion) Continuous
Study: NCT01698060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ND1.1
Study: NCT02106793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomicin C
Description: Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
Study: NCT02066298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone 220mcg BID
Description: Mometasone is an ICS
Study: NCT03856294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rikkunshito
Description: Rikkunshito, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
Study: NCT02637947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter ablation using magnetic navigation
Description: elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation using manual navigation
Description: elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.
Study: NCT01292499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: 10 sessions (50 min)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: 7 sessions + 7 phone calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation and psychotherapy
Description: Psychoeducation + psychotherapy
Study: NCT02066298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone 220mcg BID
Description: Mometasone is an ICS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone 220mcg BID
Description: Mometasone is an ICS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone 220mcg BID
Description: Mometasone is an ICS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone 220mcg BID
Description: Mometasone is an ICS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone 220mcg BID
Description: Mometasone is an ICS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5mcg QD
Description: Tiotropium is a LMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5mcg QD
Description: Tiotropium is a LMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5mcg QD
Description: Tiotropium is a LMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5mcg QD
Description: Tiotropium is a LMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5mcg QD
Description: Tiotropium is a LMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5mcg QD
Description: Tiotropium is a LMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02454426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: open label treatment
Study: NCT02106793

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Identical placebo solution
Description: Identical placebo solution
Study: NCT01417208

Intervention type: DEVICE
Intervention: SNaP® Wound Care System
Description: Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
Study: NCT04542993

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Picolinate
Description: Zinc Picolinate (50 mg PO TID x 5 days)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol 2 grams po BID x 5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Zinc Picolinate Placebo
Description: Zinc Picolinate Matched Placebo PO TID x 5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol Placebo
Description: Resveratrol Matched Placebo PO BID x 5 days
Study: NCT04593992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HTEMS
Description: high-tone external muscle stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo stimulation
Study: NCT00297453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based smoking treatment
Description: All participants have access to an Internet-based self-help intervention that includes social support through message boards. All participants have access to 10 weeks of nicotine replacement treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Counseling
Description: Six individual counseling sessions are provided over a 12 week treatment period. Participants also have access to a 10-week nicotine replacement treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-help
Description: Participants receive a self-help manual and have access to a 10 nicotine replacement treatment.
Study: NCT01169857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
Study: NCT04180371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT5528
Description: Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT5528
Description: Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT5528
Description: Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.
Study: NCT03299140

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Family Focused Therapy
Study: NCT03855215

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ACTIM CRP Rapid Test (Medix, Biochemica)
Description: The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI. healthcare workers can decide to follow the test results or not.
Study: NCT05361473

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The NeoHilda Point of care method
Description: This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Traditional evaluation
Description: Traditional way of evaluation
Study: NCT02398097

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agripal
Description: 2011/2012 influenza season standard dose trivalent subunit inactivated intramuscular vaccine, single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IDflu9μg
Description: 2011/2012 influenza season reduced-content intradermal split vaccine, single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IDflu15μg
Description: 2011/2012 influenza season standard-content intradermal split vaccine, single dose
Study: NCT03574792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04180371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive nivolumab at 480mg intravenous infusion every 4 weeks.
Study: NCT03574792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Hydrochloride Extended Release
Description: Given PO
Study: NCT03223818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast-track peri-operative program
Description: Patients who are scheduled for elective liver resection will be screened in clinic or in wards for the eligibility for ERAS program. Patient will then visit a nurse-led clinic for pre-operative assessment of risk adjustment and education. A guided tour on surgical ward and an information booklet about preoperative management will be given.~All patients will receive local infiltration of local anaesthesia (0.25% levobupivacaine) followed by continuous wound instillation using the On-Q PainBuster System balloon pump. Pain control will be supplemented by using opioid-sparing multimodal analgesia.
Study: NCT01265953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFN-rich broccoli sprout extract capsules
Description: Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of SFN, 2 capsules (1 capsule B.I.D.) daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gelatin capsule containing microcrystalline cellulose.
Description: Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
Study: NCT02066454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: 2.5mg x 2 per day during 6 months
Study: NCT03423537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: the addition of hCG (Pregnyl®, MSD Greece) will begin with the administration of gonadotrophin at a dose of 100 IU per day, administered subcutaneously, and will continue until the administration of hCG for follicular maturation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100IU per day containing N/S 0.9% will be injected
Study: NCT04560322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet, taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Capsule, taken by mouth
Study: NCT04169906

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo once daily for 7 consective days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo once daily for 7 consective days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo once daily for 7 consective days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo once daily for 7 consective days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TS-142, 10 mg
Description: Participants will receive 10 mg of TS-142 once daily for 7 consective days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142, 10 mg
Description: Participants will receive 10 mg of TS-142 once daily for 7 consective days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142, 10 mg
Description: Participants will receive 10 mg of TS-142 once daily for 7 consective days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142, 10 mg
Description: Participants will receive 10 mg of TS-142 once daily for 7 consective days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TS-142, 20 mg
Description: Participants will receive 20 mg of TS-142 once daily for 7 consective days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142, 20 mg
Description: Participants will receive 20 mg of TS-142 once daily for 7 consective days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142, 20 mg
Description: Participants will receive 20 mg of TS-142 once daily for 7 consective days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142, 20 mg
Description: Participants will receive 20 mg of TS-142 once daily for 7 consective days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TS-142, 30 mg
Description: Participants will receive 30 mg of TS-142 once daily for 7 consective days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142, 30 mg
Description: Participants will receive 30 mg of TS-142 once daily for 7 consective days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142, 30 mg
Description: Participants will receive 30 mg of TS-142 once daily for 7 consective days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142, 30 mg
Description: Participants will receive 30 mg of TS-142 once daily for 7 consective days
Study: NCT04056598

Intervention type: DIAGNOSTIC_TEST
Intervention: Study of humoral immunity
Description: Analysis: Surface antigen ELISA, recognition of living P. acnes bacteria via FACS, 16SRNA study of microbiome, SLST typing of P. acnes bacteria

Intervention type: DIAGNOSTIC_TEST
Intervention: Study of humoral immunity
Description: Analysis: Surface antigen ELISA, recognition of living P. acnes bacteria via FACS, 16SRNA study of microbiome, SLST typing of P. acnes bacteria
Study: NCT01825551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony Stimulating Factor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00664612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq
Description: Laryngoscopy with AirTraq

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq
Description: Laryngoscopy with AirTraq
Study: NCT01979926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Broussonetia spp and Lonicera spp
Description: 600 mg/ day or 1200 mg/ day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Broussonetia spp and Lonicera spp
Description: 600 mg/ day or 1200 mg/ day for 7 days
Study: NCT04117711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-007
Description: AT-007 will be administered once daily before breakfast. Up to 4 different dose cohorts in part A; up to 4 dose cohorts in part B, up to 2 dose cohorts for part C, and up to 3 dose cohorts for part D will be enrolled in the study. The starting dose in Part A will be 0.5 mg/kg as a single dose. Subsequent doses in Part A and all doses in Parts B, C, and D will be based on the results of previous cohorts and/or previous parts of the study. Part B will start after all subjects in Part A have completed the study. Cohort C1 will be conducted simultaneously with Cohort B3 and using the same dose as Cohort B2. The dose for Cohort D1 will not be higher than the dose for Cohort B2. The second and third cohorts in Part D (D2 and D3) will not start until after all subjects in Cohorts B3 and B4, respectively, have completed the study and the dose levels will not be higher than those for Cohorts B3 and B4, respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered once in the morning before breakfast
Study: NCT03455153

Intervention type: OTHER
Intervention: Physical activity monitoring
Description: COPD patients will wear an accelerometer and complete questionnaires related to daily physical activity levels for 7 days before returning for a clinic visit.
Study: NCT01979926

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combination of Broussonetia spp and Lonicera spp
Description: 600 mg/ day or 1200 mg/ day for 7 days
Study: NCT04029727

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination of Plant Extracts (BSL_EP025)
Description: Each participant will consume 2 capsules daily at lunch for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 2 capsules daily at lunch for 8 weeks.
Study: NCT03192566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: Dosing of Tylenol for post operative pain control
Study: NCT01881217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1179470
Description: BAY1179470 will be administered as a 1-hour intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1179470
Description: BAY1179470 will be administered as a 1-hour intravenous infusion.
Study: NCT01016730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study: NCT01881217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1179470
Description: BAY1179470 will be administered as a 1-hour intravenous infusion.